18F-FDG PET/CT in Breast Cancer: Evidence-Based Recommendations in Initial Staging

This is a clinical practice guideline on the role and appropriateness of fluorodeoxyglucose positron emission tomography – computed tomography (18F-FDG PET/CT) for initial breast cancer staging and its therapeutic and prognostic impact. Recommendations are stratified by risk, and outcomes of interest include sensitivity, specificity, change in stage compared to staging done by conventional imaging, prognosis, and costs. The guideline also addresses the association of metabolic information with biology and prognosis.